Novo Nordisk's diabetes portfolio boosted as Tresiba and Ryzodeg cleared in Europe
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorisation for Novo Nordisk's Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults.